Patients with MS that clinically responded to aHSCT in a phase II clinical trial, had higher memory CD4+ and CD8+ T cell counts pre-aHSCT compared with non-responders (15) and for SSc the same trend in higher complete CD4+ and CD8+ T cell counts pre-aHSCT for the responders was observed (16). Here, CD8A is linked to myeloid sarcoma.